Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.
Title | Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Fontalis, A., Kenanidis E., Kotronias R. Angelos, Papachristou A., Anagnostis P., Potoupnis M., & Tsiridis E. |
Journal | Expert Opin Pharmacother |
Volume | 20 |
Issue | 9 |
Pagination | 1123-1134 |
Date Published | 2019 06 |
ISSN | 1744-7666 |
Keywords | Bone Density Conservation Agents, Diphosphonates, Female, Humans, Osteoporosis |
Abstract | INTRODUCTION: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique biologic pathways such as the Wnt/β-catenin pathway have been targeted in the quest for new emerging therapeutic strategies.AREAS COVERED: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of-the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects.EXPERT OPINION: Bisphosphonates appear to be a reliable and cost-effective option, whereas denosumab has introduced a simpler dosing regimen and may achieve a linear increase in bone mineral density (BMD) with no plateau being observed, along with continuous anti-fracture efficacy. Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces bone formation and suppresses bone resorption, has also been developed and shown a significant reduction in fracture incidence; however, concerns have arisen with regard to increased cardiovascular risk. |
DOI | 10.1080/14656566.2019.1594772 |
Alternate Journal | Expert Opin Pharmacother |
PubMed ID | 30958709 |